Evidence map›Paper›PMID 42181475›Full record

ArticleCureus2026

High-Risk Pulmonary Embolism: A Second Opportunity for Thrombolysis.

Joana Luís, Ana M de Oliveira, André C Oliveira, Margarida Vera-Cruz, João Gonçalves Pereira

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joana LuísIntensive Care Unit, Unidade Local de Saúde Estuário do Tejo, Vila Franca de Xira, PRT.
Ana M de OliveiraIntensive Care Unit, Unidade Local de Saúde Estuário do Tejo, Vila Franca de Xira, PRT.
André C OliveiraIntensive Care Unit, Unidade Local de Saúde Estuário do Tejo, Vila Franca de Xira, PRT.
Margarida Vera-CruzIntensive Care Unit, Hospital CUF Tejo, Lisbon, PRT.
João Gonçalves PereiraIntensive Care Unit, Unidade Local de Saúde Estuário do Tejo, Vila Franca de Xira, PRT.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pulmonary embolism (PE) remains a major cause of cardiovascular mortality. High-risk PE is characterized by acute cor pulmonale, persistent hypotension, hypoperfusion, obstructive shock, and, in extreme cases, cardiopulmonary arrest. Systemic thrombolysis is recommended for high-risk PE; however, treatment failure may occur in a subset of patients. Rescue options include surgical embolectomy or a second systemic thrombolysis when hemodynamic instability persists. A 71-year-old woman presented to the hospital with sudden-onset dyspnea and severe hypoxemia. Acute cor pulmonale with obstructive shock was diagnosed, and urgent systemic thrombolysis with Alteplase ® (Boehringer Ingelheim, Germany) was started, with initial improvement. Approximately 15 hours later, there was a new significant clinical deterioration, with refractory shock, severe hypoperfusion, and respiratory failure. In the absence of eligibility for surgical or endovascular intervention, a second systemic thrombolysis was performed, resulting in gradual but progressive clinical recovery. She was discharged from the intensive care unit on day 20, eupneic and without supplemental oxygen. Repeat systemic thrombolysis should be considered in high-risk PE that recurs after a first thrombolysis, when reperfusion strategies, such as endovascular therapy or surgery, are not feasible. This case highlights the potential life-saving role of repeated thrombolysis in select critical-care scenarios.

Indexed as

high-risk pulmonary embolismobstructive shockrepeated thrombolysisreperfusion strategiesrescue therapy

Identifiers

PMID42181475
PMCPMC13192759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.